Details of T-Cell Doses Infused and Response to DLI
| Patient No. . | Time From Relapse or Progression to DLI (wk) . | No. of T Cells Infused (×107/kg) . | Time From Prior Infusion (wk) . | Response of Disease . | Time From DLI to Response (wk) . | Duration of Response (mo) . | GVHD (acute/chronic) . | T-Cell Chimerism Before DLI . | Survival After DLI (mo) . | Causes of Death . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 33 | — | CR | 6 | 38+ | 3/extensive | Donor | 38+ | |
| 2 | 16 | 16 | — | NR | NA | — | 0/nil | ND | 28 | Progressive disease |
| 3 | 32 | 7 | — | NR | NA | — | 1/nil | Donor | 17+ | |
| 4 | 24 | NR | NA | — | 0/nil | Donor | ||||
| 8 | 9 | NR | NA | — | 0/nil | Donor | ||||
| 8 | 20 | NR | NA | — | 0/nil | Donor | ||||
| 4 | 13 | 5 | — | NR | NA | — | 0/nil | ND | 26+ | |
| 10 | 12 | NR | NA | — | 2/nil | ND | ||||
| 25 | 22 | PR | 10 | 5* | 3/limited | |||||
| 14 | 44 | PR (NA) | 4 | 3+ | 0/nil | Donor | ||||
| 5 | 12 | 12 | — | CR | 7 | 14 | 2/limited | Donor | 25+ | |
| 24 | 1 | 82 | NR | NA | — | 0/nil | Donor | |||
| 10 | 9 | NE | NA | — | NE | |||||
| 6 | 10 | 9 | — | NR | NA | — | 0/nil | Donor | 20+ | |
| 8 | 9 | NR | NA | — | 0/nil | Donor | ||||
| 10 | 32 | NR | NA | — | 0/nil | Donor | ||||
| 20 | 12 | NR | NA | — | 0/nil | Donor | ||||
| 7 | 68 | 7 | — | CR | 8 | 18+ | 3/extensive | Mixed | 18+ | |
| 8 | 1 | 8 | — | PR | 5 | 2s | 3/NE | Mixed | 3 | Septicemia |
| 9 | 112 | 3 | — | NR | NA | — | 1/limited | Donor | 9 | Septicemia |
| 6 | 18 | PR | 6 | 3s | 1/limited | |||||
| 10 | 11 | 5 | — | PR | 5 | 2+ | 0/nil | Donor | 7+ | |
| +0.3 × 106 | CD34/kg | |||||||||
| 15 | 7 | CR | 5 | 7+ | 3/limited | |||||
| +0.6 × 106 | CD34/kg | |||||||||
| 11 | 28 | 5 | — | NR | NA | — | 0/nil | Donor | 6+ | |
| 10 | 10 | NR | NA | 0/nil | ||||||
| 12 | 12 | 0.1 | — | PR | 6 | 4+ | 0/nil | Donor | 8+ | |
| 1 | 14 | NE | NA | — | 0/nil | |||||
| 13 | 34 | 3 | NR | NA | — | 2/nil | ND | 5+ | ||
| 5 | 16 | NE | NA | NE |
| Patient No. . | Time From Relapse or Progression to DLI (wk) . | No. of T Cells Infused (×107/kg) . | Time From Prior Infusion (wk) . | Response of Disease . | Time From DLI to Response (wk) . | Duration of Response (mo) . | GVHD (acute/chronic) . | T-Cell Chimerism Before DLI . | Survival After DLI (mo) . | Causes of Death . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 33 | — | CR | 6 | 38+ | 3/extensive | Donor | 38+ | |
| 2 | 16 | 16 | — | NR | NA | — | 0/nil | ND | 28 | Progressive disease |
| 3 | 32 | 7 | — | NR | NA | — | 1/nil | Donor | 17+ | |
| 4 | 24 | NR | NA | — | 0/nil | Donor | ||||
| 8 | 9 | NR | NA | — | 0/nil | Donor | ||||
| 8 | 20 | NR | NA | — | 0/nil | Donor | ||||
| 4 | 13 | 5 | — | NR | NA | — | 0/nil | ND | 26+ | |
| 10 | 12 | NR | NA | — | 2/nil | ND | ||||
| 25 | 22 | PR | 10 | 5* | 3/limited | |||||
| 14 | 44 | PR (NA) | 4 | 3+ | 0/nil | Donor | ||||
| 5 | 12 | 12 | — | CR | 7 | 14 | 2/limited | Donor | 25+ | |
| 24 | 1 | 82 | NR | NA | — | 0/nil | Donor | |||
| 10 | 9 | NE | NA | — | NE | |||||
| 6 | 10 | 9 | — | NR | NA | — | 0/nil | Donor | 20+ | |
| 8 | 9 | NR | NA | — | 0/nil | Donor | ||||
| 10 | 32 | NR | NA | — | 0/nil | Donor | ||||
| 20 | 12 | NR | NA | — | 0/nil | Donor | ||||
| 7 | 68 | 7 | — | CR | 8 | 18+ | 3/extensive | Mixed | 18+ | |
| 8 | 1 | 8 | — | PR | 5 | 2s | 3/NE | Mixed | 3 | Septicemia |
| 9 | 112 | 3 | — | NR | NA | — | 1/limited | Donor | 9 | Septicemia |
| 6 | 18 | PR | 6 | 3s | 1/limited | |||||
| 10 | 11 | 5 | — | PR | 5 | 2+ | 0/nil | Donor | 7+ | |
| +0.3 × 106 | CD34/kg | |||||||||
| 15 | 7 | CR | 5 | 7+ | 3/limited | |||||
| +0.6 × 106 | CD34/kg | |||||||||
| 11 | 28 | 5 | — | NR | NA | — | 0/nil | Donor | 6+ | |
| 10 | 10 | NR | NA | 0/nil | ||||||
| 12 | 12 | 0.1 | — | PR | 6 | 4+ | 0/nil | Donor | 8+ | |
| 1 | 14 | NE | NA | — | 0/nil | |||||
| 13 | 34 | 3 | NR | NA | — | 2/nil | ND | 5+ | ||
| 5 | 16 | NE | NA | NE |
Abbreviations: NE, not evaluable; NA, not applicable; ND, not done; S, sensored; NR, no response; CR, complete response.
Relapse was treated with VAD (3×) and intermediate-dose melphalan (70 mg/m2 IV).